New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
07:55 EDTKYTHKythera price target raised to $55 from $50 at Leerink
Leeirnk raised its price target for Kythera shares to $55 after its survey indicated "significant demand" for the company's ATX-101, which aims to reduce submental fat. The firm keeps an Outperform rating on the stock.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
09:00 EDTKYTHKYTHERA rises after FDA releases docs ahead of double-chin injection meeting
Shares of Kythera Biopharmaceuticals (KYTH) are rising in pre-market trading after the FDA released briefing documents for an advisory committee meeting to discuss the company's deoxycholic acid, or DCA, that is planned for March 9. Kythera is seeking approval for DCA for the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults, more commonly known as "double-chin." In the general summary of the documents, FDA staff wrote: "The currently available data support a favorable benefit-risk assessment for the use of DCA for the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. No major safety issues associated with the use of DCA have been identified to date." In pre-market trading, Kythera shares are up 26.6% to $50.50.
March 2, 2015
16:59 EDTKYTHKYTHERA reports Q4 EPS ($1.07), consensus ($1.07)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use